Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. (linkinghub.elsevier.com)

Authors: Cummings JL … Feldman HH Journal: The Lancet Published: 2026-05-30 DOI: https://doi.org/10.1016/S0140-6736(26)00459-9